Author: Ravi Shankar

September 28, 2026
News release

Unlocking the Growth – Invitation to BioPorto’s investor meeting on October 7 

As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company’s future.

At the event, management will provide an update on BioPorto’s commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cash flow positivity. Participants will also hear independent perspectives from leading clinical experts and capital market specialists on the opportunities created by biomarker-guided diagnostics and the updated KDIGO guidelines.

Key topics include:
✅ Commercial momentum and strategic priorities
✅ Adult Clinical Validation Study update
✅ What the new KDIGO guidelines could mean for biomarker adoption
✅ External perspectives on BioPorto’s investment case and future value drivers
✅ Live Q&A with management and guest speakers

Wednesday, October 7, 2026
3:00 PM – 5:30 PM CET (Registration from 2:30 PM)
 BioPorto A/S, Tuborg Havnevej 15, 2900 Hellerup, Denmark

Register today to secure your participation and gain first-hand insights into BioPorto’s strategy, clinical progress, and future growth opportunities.
Register in the link in the invitation attached or via this link: https://lnkd.in/ej4e8P65

We look forward to welcoming you to BioPorto.

For further information, please contact:

BioPorto A/S
Klaus Juhl Wulff, BioPorto A/S, investor@bioporto.com, C: +45 25 63 39 90

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

• bioporto-ir-event-invitation-oct-7th-2026

28 SEPTEMBER 2026

NORTHERN 2 VCT PLC

TRANSACTION IN OWN SHARES 

Northern 2 VCT PLC (“the Company”) announces that on 25 September 2026 it purchased for cancellation under an existing authority granted by shareholders 1,275,232 ordinary shares of 5p each in the market at a price of 52.63p per share, representing approximately 0.48% of the Company’s issued ordinary share capital. There remain 266,589,293 ordinary shares in issue. 

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), the Company notifies the market that the capital of the Company consists of 266,589,293 ordinary shares with a nominal value of 5p each.  All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 266,589,293 (“the Figure”). The Figure may be used by a shareholder or other person as the denominator for the calculations by which they will determine if they are required to notify the voting rights they hold in relation to the Company, or a change to those voting rights, under the DTRs. 

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

The contents of the Mercia Asset Management PLC website and the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website) are not incorporated into, nor form part of, this announcement.

28 SEPTEMBER 2026

NORTHERN VENTURE TRUST PLC

TRANSACTION IN OWN SHARES 

Northern Venture Trust PLC (“the Company”) announces that on 25 September 2026 it purchased for cancellation under an existing authority granted by shareholders 1,659,577 ordinary shares of 25p each in the market at a price of 55.67p per share, representing approximately 0.64% of the Company’s issued ordinary share capital. There remain 258,557,032 ordinary shares in issue. 

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), the Company notifies the market that the capital of the Company consists of 258,557,032 ordinary shares with a nominal value of 25p each. All the ordinary shares have voting rights.  The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 258,557,032 (“the Figure”). The Figure may be used by a shareholder or other person as the denominator for the calculations by which they will determine if they are required to notify the voting rights they hold in relation to the Company, or a change to those voting rights, under the DTRs.

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction

Please find attached the DNO ASA Statement Regarding Final Offer for Capricorn Energy plc of 28 September 2026.

–

For further information, please contact:
Media: media@dno.no
Investors: investor.relations@dno.no

–

DNO ASA is a Norwegian oil and gas operator active in the North Sea and the Middle East. Founded in 1971, DNO is Norway’s oldest oil company and the first to list on the Oslo Stock Exchange in 1981. The Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in Norway, the Kurdistan region of Iraq, the United Kingdom and Yemen. More information is available at www.dno.no.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachment

• Statement Regarding Final Offer for Capricorn Energy plc

• Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits¹ as of June 30, 2026
• Cash runway guidance remains unchanged from July 30, 2026²
• Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026
• Key highlights from the first half of 2026 and recent Company updates
• Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results

Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.

Key Financial Results for the First Half of 2026

(in thousands of euros)		Six Months Ended
		June 30, 2026		June 30, 2025
Revenues		20		4,454
Other income		1,286		1,156
Research and development expenses		(46,238)		(44,890)
Marketing – business development expenses		(2,589)		(746)
General and administrative expenses		(22,247)		(14,713)
Other operating income (expenses)		(619)		(8,202)
Net Operating Loss		(70,388)		(62,940)
Net Financial Income (Loss)		907		(113,224)
Share of net loss- Equity method and dilution gain		117		(220)
Income tax		(104)		503
Net Loss for the Period		(69,467)		(175,882)
Basic/diluted loss per share (euros/share)		(0.25)		(1.62)
Weighted average number of outstanding shares used for computing basic/diluted loss per share		273,582,870		108,839,636

There were no revenues recorded for the first half of 2026, compared to €4.5 million generated for the same period in 2025. Revenue recognized in the first half of 2025 was attributable to the 2022 License Agreement with Chia Tai Tianging Pharmaceutical Group Co., Ltd. (as amended and assigned to Chia Tai Tianging (Guangzhou) Co., Ltd).

Other income amounted to €1.3 million for the first half of 2026, stable as compared to €1.2 million for the first half of 2025. Other income mainly consisted of the French research tax credit (“Crédit d’Impôt Recherche”).

R&D expenses for the first half of 2026 amounted to €46.2 million, mainly driven by the clinical development of lanifibranor in MASH, up 3.0% compared to the €44.9 million for the first half of 2025. This increase was in line with operational plan expectations and did not include any preclinical research expenses following the discontinuation of preclinical R&D activities implemented mid-2025.

Marketing and business development expenses amounted to €2.6 million for the first half of 2026, compared to €0.7 million for the same period in 2025, primarily reflecting increased personnel costs and expenses related to preparations for the potential commercial development of lanifibranor, if approved.

General and administrative expenses (G&A) amounted to €22.2 million in the first half of 2026, compared to €14.7 million in the first half of 2025, an increase of €7.5 million. The change was primarily related to €4.7 million of increase in personnel costs, including share-based compensation expenses, consulting fees and other expenses associated with potential commercial development of lanifibranor, if approved.

Net financial income (loss) amounted to €0.9 million in the first half of 2026, compared to (€113.2) million for the same period in 2025. The financial result for the first half of 2026 mainly reflected (i) €16.2 million of non-cash impact from the IFRS fair value accounting of financial instruments entered into in connection with the restructuring of warrants issued to European Investment Bank (“EIB”), the Lenders’ Warrants issued to funds and accounts managed by BlackRock and Claret Capital Partners (together, the “Lenders”) and the embedded convertible option in the first tranche of €35.0 million of senior secured convertible bonds issued under the June 2026 debt financing with the Lenders for up to €130.0 million (the “Debt Financing”), (ii) €4.8 million of income from cash equivalents and foreign exchange gains (net), and (iii) (€20.0) million of interest and related financial expenses, including (€11.2) million resulting from the repayment of the loan with the EIB and (€7.4) million of interest expense related to the royalty certificates issued in 2023 and 2024.

The Company’s net loss stood at (€69.5) million as of June 30, 2026, compared to (€175.9) million as of June 30, 2025.

As of June 30, 2026, the Company’s cash and cash equivalents amounted to €166.1 million and €67.8 million in short-term deposits¹, compared to cash and cash equivalents of €99.3 million and €131.6 million in short-term deposits as of December 31, 2025.

Net cash used in operating activities amounted to (€45.4) million for the first half of 2026, compared to (€53.7) million for the same period in 2025. The lower cash consumption mainly reflects the favorable working capital change partially offset by the increase in operating expenses relating to the continued advancement of the NATiV3 Phase 3 clinical trial and preparation of pre-commercial activities.

Net cash generated from investing activities for the first half of 2026 amounted to €63.8 million, compared to (€24.8) million for the first half of 2025. The increase primarily reflects changes in the Company’s short-term deposits, including in connection with the June 2026 comprehensive refinancing transaction³.

Net cash generated from financing activities for the first half of 2026 amounted to €47.7 million, compared to €104.8 million for the first half of 2025.The net cash generated from financing activities in the first half of 2026 reflects the comprehensive refinancing transaction announced on June 2, 2026, including the offering of 27,272,727 American Depositary Shares (the “Equity Offering”) for €103.0 million and the Tranches A and B of the Debt Financing of €75.0 million, both in gross proceeds. These cash inflows were partially offset by the repayment in full of the existing EIB loans for an aggregate amount of €62.2 million, and the repurchase of all of the warrants issued to EIB in connection with the first tranche of the EIB loans and 700,000 of the warrants issued to EIB in connection with the second tranche of the EIB loans for an aggregate repurchase price of €50.0 million⁴. The net cash generated from financing activities in the first half of 2025 came from the gross proceeds of €115.6 million (net proceeds of €108.0) of the 2024 Structured Financing⁵.

Based on the Company’s existing cash and cash equivalents and short-term deposits, together with the net proceeds from the completed Equity Offering, the completed EIB Transactions and the issuance of Tranches A and B under the Debt Financing Transaction⁶, the Company expects to be able to finance its operations as currently planned until the end of the second quarter of 2027. At the date of this press release, the Company’s current cash and cash equivalents are not sufficient to cover operating needs as currently planned for the next twelve months.

If Tranche C of the Debt Financing Transaction³ is issued for potential gross proceeds of up to €55.0 million and the Tranche 3 warrants previously issued by the Company in the Structured Financing⁵ for potential gross proceeds of up to €116.0 million are exercised in full, the Company expects to be able to finance its operations as currently planned until the start of the first quarter of 2028⁷.

Over the first half of 2026, the Company recorded a positive foreign exchange effect on cash and cash equivalents of €0.7 million, compared with a negative effect of (€0.7) million for the first half of 2025, primarily due to the changes in the EUR/USD exchange rate.

Corporate Updates

• On September 2, 2026, Inventiva announced that the last patient had completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis⁸.
• NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort.
• Inventiva expects to report topline results from the Phase 3 clinical trial NATiV3 in the fourth quarter of 2026.
• If the NATiV3 topline results are favorable, the Company anticipates regulatory submission in the first half of 2027 and is preparing for a potential U.S. launch of lanifibranor in 2028, subject to U.S. Food and Drug Administration (“FDA”) approval.
• Since the start of 2026, Inventiva strengthened its leadership team with the appointment of Axel-Sven Malkomes as Chief Financial Officer, Susan Coles, as Chief Legal Officer, Pamela Herbster as Chief People Officer⁹ and Chris Benecchi, as Chief Operating Officer¹⁰.
• Barbara Krebs-Pohl, Anne Prener, and Camilla Soenderby, were appointed as independent members of the Company’s Board of Directors, effective June 30, 2026, reflecting the additional expertise, international reach, and strategic acumen required to guide the Company through its next phase of development and potential commercialization¹¹.

First-Half Financial Results Webcast

Inventiva’s management will hold a conference call in English, followed by a Q&A session, on Monday, September 28, 2026, at 8:00 AM (New York), 2:00 PM (Paris) to discuss first-half financial results for 2026. Participants wishing to join the conference call by phone and ask questions must register in advance here. Upon registration, participants will receive dial-in details by email. The live webcast may be accessed on the Events section of the Inventiva website. A replay of the conference call will be available after the event on the Company’s website.

Upcoming Scientific Conference Participation

The American Association for the Study of Liver Diseases (AASLD), Denver, CO, November 5-9, 2026.

Next Financial Results Publication

Revenues and cash and cash equivalents for the third quarter 2026 on Monday November 23, 2026 (before E.U. and U.S. market open).

About Lanifibranor

Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
https://www.inventivapharma.com

Contacts

Investor Relations

David Nikodem: IR@inventivapharma.com

Media Relations

Lisa Buffington: media@inventivapharma.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “estimate,” “may,” “will,” “could,” “should,” “designed,” “hope,” “target,” “potential,” “opportunity,” “possible,” “aim,” and “continue” or similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited to, statements concerning the potential therapeutic benefit of lanifibranor, the expected availability and timing of results from NATiV3, the timing of potential regulatory submissions, approvals and commercialization of lanifibranor, Inventiva’s cash resources and expenses and ability to obtain additional financial resources, including assumptions and conditions relating thereto with, and Inventiva’s future activities, expectations, plans, growth and prospects. Although Inventiva’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that such forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Inventiva, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, contingencies and uncertainties include, among other things, uncertainties inherent in research and development, clinical data and analysis and decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any product candidates, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; Inventiva’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; Inventiva’s ability to achieve milestones; Inventiva’s ability to obtain adequate financing to fund its operations and continue as a going concern, including Inventiva’s ability to enter into potential transactions on the expected timing or at all, Inventiva’s ability to comply with and satisfy the terms and conditions of its financing documents and whether, when and to what extent the securities issued in the Debt Financing and other dilutive instruments, including the Tranche 3 warrants, may be exercised; Inventiva’s ability to execute on its strategy, including with respect to commercialization, marketing and manufacturing; potential negative impacts on Inventiva from changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, and ongoing conflicts, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, and the other risks and uncertainties described in Inventiva’s Universal Registration Document for the year ended on December 31, 2025 filed with the Autorité des Marchés Financiers on April 8, 2026, Inventiva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on April 8, 2026 and Inventiva’s Half-Year Report for the fiscal period ended June 30, 2026, filed on Form 6-K on September 28, 2026 including those described under the caption “Risk Factors”, and in future filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Inventiva disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that Inventiva becomes aware of, except as required by law.

---

¹ Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available.
² Cf press release of July 30, 2026.

³ Cf press release of June 2, 2026
⁴ Cf press releases of June 2, 2026, and June 12, 2026.
⁵ Cf press release of October 13, 2024.

⁶ Cf press release of June 2, 2026 (please refer to the description of the financial covenants pertaining to the Debt Financing).
⁷ These estimates are based on the Company’s current business plan and assume the successful issuance of Tranche C of the Debt Financing, and the exercise in full of the Tranche 3 warrants previously issued by the Company in the Structured Financing for potential proceeds of up to €116.0 million, and exclude any potential milestones payable to or by the Company and any additional expenditures related to the product candidate or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. These estimates may be shortened in the event of an increase, in expenditure relating to the development programs beyond the Company’s expectations, or if the development program progresses more quickly than expected.

⁸ Cf press release of September 2, 2026.

⁹ Cf press release of April 22, 2026.
¹⁰ Cf press release of August 31, 2026.
¹¹ Cf press release of July 8, 2026.

Attachment

• Inventiva – PR – H1 2026 Financial Results – EN – 09 28 2026

• Six equipment items already in stock, together with the associated engineering: 75% of the €3.2 million to be received within 30 days of a delivery scheduled before the end of 2026, with no significant industrial cash outlay;
• A majority of the revenue to be recognised in the current financial year;
• INCAD: the first in a network of some twenty Multi-Energy Hubs in Quebec.

 

Vitry-le-François, France – 28 September 2026, 08:00 am (CEST)

Haffner Energy announces the signing of a contract for a firm €3.2 million order with INCAD (Centre d’Intégration de CArburants Durables), the project company responsible for developing the first Multi-Energy Hub in Bécancour, at the heart of Quebec’s Energy Transition Valley.

Effective upon signature on 25 September 2026, the contract covers six equipment items already manufactured and available in stock, together with the associated engineering services. The project’s remaining equipment will be manufactured in Canada under licence from Haffner Energy.

A compressed payment schedule

The contract provides for a €480,000 down payment, representing 15% of the total amount, due no later than 12 October 2026. Within thirty days of FOB delivery of the equipment, 75% of the contract price will have been invoiced and received.

Delivery is scheduled before the end of 2026, subject to international transport and logistics constraints. This will allow work to bring the equipment into compliance with Canadian standards to begin immediately.

A rapid contribution to cash flow, revenue and earnings

As the six items of equipment to be exported will be drawn from Haffner Energy’s existing inventory, their manufacturing costs have already been incurred and paid. Fulfilment of the order will therefore generate rapid cash inflows without any significant new industrial cash outlay.

As revenue is recognised on a percentage-of-completion basis, based on costs incurred, the allocation to the contract of this already-manufactured equipment is expected to enable a majority of the contract revenue to be recognised in the current financial year, with a corresponding contribution to earnings.

An order complementing the licence agreement for the Canadian market

The contract announced today is legally and economically separate from the licence agreement entered into with Mundi Énergies. This agreement covers the deployment of Haffner Energy’s technology across the entire Canadian market, beyond the INCAD project alone. In this respect, Haffner Energy has already received an initial licence payment (upfront fee) of €1 million and, in consideration for the licence, holds a 49% stake in Mundi Haffner Technologies Inc., the company responsible for developing the technology in Quebec.

INCAD: the first project in a large-scale Canadian programme

Located in the Bécancour Industrial and Port Park, at the heart of Quebec’s Energy Transition Valley, INCAD is developing the first Multi-Energy Hub resulting from the partnership between Haffner Energy and Mundi Énergies. The INCAD unit is designed to produce primarily 400 Nm³/h of renewable natural gas (RNG) from residual biomass. Commissioning is scheduled for the second quarter of 2028.

The site will also produce biochar, which can notably be used as a soil amendment. Biochar contributes to soil regeneration and enables the long-term sequestration of approximately three times its own weight in CO₂ equivalent.

A portion of the thermolysis oil produced will be reserved for demonstration campaigns for the production of renewable diesel and renewable aviation fuel, with a view to qualifying the SB-HEFA process for the production of sustainable aviation fuel (SAF).

INCAD will thus demonstrate, on an industrial scale, Haffner Energy technology’s ability to convert a single resource into RNG, biochar and liquid fuels.

INCAD is the first in a network of some twenty Multi-Energy Hubs that Haffner Energy and Mundi Énergies plan to develop progressively across Quebec. Subsequent projects will target significantly higher capacities. For Haffner Energy, this model combines several revenue streams: sales of proprietary equipment, engineering, licence royalties, maintenance and operations, local manufacturing under licence and minority stakes in project companies.

Mundi Énergies and Haffner Energy prepare the next stages of deployment

The order was signed during the third visit to France by a Mundi Énergies delegation since summer 2025. Comprising Lilianne Trudel, Christian Blais and Sylvain Perreault, the team was able to see Haffner Energy’s H6 equipment in operation at the Marolles site.

Sylvain Perreault, President of Mundi Énergies, said:

“Our engineering team had already been very favourably impressed by the H4 generation in July 2025. Having both the H4 equipment and the new H6 generation at the same site provides a particularly compelling illustration of the progress achieved by Haffner Energy, notably in terms of simplification and industrial design. We were also able to see the H6 in operation for the first time.

The modularity of the H6 solution represents a decisive advantage for us. In a country such as Canada, where winters are extremely harsh and the various phases of on-site work have to be organised taking into account weather-related uncertainties and long distances, the ability to produce factory-pretested modules provides much greater control over project schedules and significantly reduces execution risks.

This third visit to France since summer 2025 has enabled us to see very concretely the progress achieved by Haffner Energy and to prepare, together with its teams, the next stages of the INCAD project in Bécancour. It has also enabled us to make significant progress on the deployment of future Multi-Energy Hubs, with several strategic sites currently moving beyond the feasibility-study stage and towards securing their biomass supply.”

Philippe Haffner, Chairman and Chief Executive Officer of Haffner Energy, said:

“Beyond its very significant contribution to the Company’s earnings and cash position, this firm order marks a new phase for Haffner Energy. Following several financial years devoted to innovation and to broadening our value proposition beyond hydrogen alone, during which revenue remained very limited, we are now entering the tangible phase of orders, deliveries and deployment, fully returning to the pace of an industrial company, with revenue set to accelerate very sharply from this year onwards.

The order from Mundi Énergies provides our shareholders with a tangible and quantifiable demonstration of our strategy: our strategic equipment and engineering expertise, combined with local manufacturing under licence, within a replicable model. As it monetises equipment already held in inventory, it directly strengthens our cash position.

The technical and industrial success of the H6, which our partners saw operating in Marolles, confirms the simplification of our platform. H6 technology is paving the way for the next projects in Quebec, which will have significantly greater capacities, as well as for our large-scale industrial deployment through the CORE100 programme.

Finally, INCAD will serve as an industrial and commercial showcase for Canada and North America: a single site producing RNG and biochar, while demonstrating our pathway to renewable diesel and, ultimately, SAF.”

About Haffner Energy

Haffner Energy designs and supplies innovative solutions for the production of competitive renewable fuels from biomass. With over 33 years’ experience using all types of biomass, the company has developed proprietary thermolysis and gasification technologies enabling the production of renewable gas, hydrogen, renewable methanol, power, and Sustainable Aviation Fuel (SAF).

As well as supplying technology, Haffner Energy supports its clients in developing industrial projects designed to accelerate the decarbonization of the energy, industrial and transport sectors. Its solutions also contribute to the production of biogenic CO₂ and biochar, thereby supporting the energy transition and the sustainable use of biomass.

Haffner Energy is listed on Euronext Growth (ISIN: FR0014007ND6 – Ticker: ALHAF)

Media contact

Laetitia Mailhes
laetitia.mailhes@haffner-energy.com 

+33 (0)6 07 12 96 76

Investor Relations
investisseurs@haffner-energy.com

Attachment

• PR_Contract INCAD_250928

OSB GROUP PLC
ISIN: GB00BLDRH360
28 September 2026

LEI number: 213800ZBKL9BHSL2K459

OSB GROUP PLC (the “Company”)
Share Buyback Programme – Transactions in Own Shares

The Company announces that, for the period from 21 September 2026 to 25 September 2026, inclusive, it had purchased a total of 191,897 of its ordinary shares of £0.01 each (the “ordinary shares“) on the London Stock Exchange, CBOE BXE ,CBOE CXE and Aquis Exchange, through the Company’s broker Jefferies International Limited as detailed below. The repurchased ordinary shares will be cancelled.

21 September 2026	London Stock Exchange	CBOE BXE	CBOE CXE	Aquis Exchange
Number of ordinary shares purchased	0	0	0	0
Highest price paid (per ordinary share)	0.00p	0.00p	0.00p	0.00p
Lowest price paid (per ordinary share)	0.00p	0.00p	0.00p	0.00p
Volume weighted average price paid (per ordinary share)	0.00p	0.00p	0.00p	0.00p

22 September 2026	London Stock Exchange	CBOE BXE	CBOE CXE	Aquis Exchange
Number of ordinary shares purchased	991	1,052	183	119
Highest price paid (per ordinary share)	520.00p	520.00p	518.50p	515.00p
Lowest price paid (per ordinary share)	513.50p	513.50p	513.50p	514.00p
Volume weighted average price paid (per ordinary share)	514.96p	514.96p	514.90p	514.92p

23 September 2026	London Stock Exchange	CBOE BXE	CBOE CXE	Aquis Exchange
Number of ordinary shares purchased	14,992	16,007	2,557	1,971
Highest price paid (per ordinary share)	514.00p	514.00p	514.00p	514.00p
Lowest price paid (per ordinary share)	508.00p	508.00p	508.00p	508.00p
Volume weighted average price paid (per ordinary share)	509.10p	509.11p	509.10p	509.11p

24 September 2026	London Stock Exchange	CBOE BXE	CBOE CXE	Aquis Exchange
Number of ordinary shares purchased	35,770	36,838	6,619	4,466
Highest price paid (per ordinary share)	509.00p	509.00p	509.00p	509.00p
Lowest price paid (per ordinary share)	503.00p	503.00p	503.00p	503.00p
Volume weighted average price paid (per ordinary share)	505.30p	505.29p	505.27p	505.29p

25 September 2026	London Stock Exchange	CBOE BXE	CBOE CXE	Aquis Exchange
Number of ordinary shares purchased	29,678	31,156	5,675	3,823
Highest price paid (per ordinary share)	510.50p	510.50p	511.00p	510.50p
Lowest price paid (per ordinary share)	504.50p	504.50p	504.50p	504.50p
Volume weighted average price paid (per ordinary share)	506.57p	506.53p	506.55p	506.55p

The purchases form part of the Company’s share buyback programme announced on 5 March 2026.

Following settlement of the above purchases and cancellation of the purchased ordinary shares, the Company’s total number of ordinary shares in issue shall be 338,454,529 ordinary shares.

No ordinary shares are held in treasury. Therefore, the total number of voting rights in the Company is 338,454,529.

In accordance with Article 5(2)(b) of Regulation (EU) No 596/2024 as incorporated into and implemented under English law (including by virtue of the European Union (Withdrawal) Act 2028), the detailed breakdown of individual trades made by Jefferies International Limited on behalf of the Company as part of the share buyback programme is set out below.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

Schedule of Purchases

Issuer Name	OSB GROUP PLC
LEI	223800ZBKL9BHSL2K459
ISIN	GB00BLDRH360
Intermediary Name	Jefferies International Limited
Intermediary Code	JEFFGB2XXXX
Timezone	GMT
Currency	GBP

Individual Transactions:

Please see attached PDF for full list of transactions.

Attachment

• 2026.09.25_OSBG Buyback Fills

PRESS RELEASE

H1 2026 results: well-managed growth and improved profitability

• H1 2026 revenue of €124.5m (+7.3%): growth driven by the Erevo acquisition and the integration of Novaprove and the DIS business, up 1.4% like-for-like
• Annual recurring revenue (ARR) of €111.1m at June 30, 2026, +8.8%, with a strong organic component
• Current EBITDA of €33.3m (+11.9%), with the EBITDA margin increasing to 26.8% from 25.7% in H1 2025
• Current operating income of €23.7m (+11.9%): the current operating margin improved to 19.0% from 18.2% in H1 2025, driven by a favourable product mix, effective cost control and accretive acquisitions
• Net profit: +10.5% to €20.0m
• Net cash position increased to €93.2m at 30 June 2026 (+€9.6m vs. 31 December 2025)

Villers-lès-Nancy, 28 September, 2026, 08:00 CEST – Equasens (ISIN: FR0012882389 – Ticker: EQS), a leading provider of digital solutions for healthcare professionals, today announced the publication of its H1 2026 results. The Equasens Board of Directors, meeting on 23 September 2026 under the chairmanship of Dominique PAUTRAT, reviewed and approved the consolidated financial statements at 30 June 2026.
        

Simplified H1 income statement (€m)	H1 2025 Reported basis	H1 2026 Reported basis	Change / Reported basis
Revenue	116.0	124.5	8.5	+7.3%
Current EBITDA	29.8	33.3	3.5	+11.9%
Current operating income	21.1	23.7	2.5	+11.9%
Net profit	18.1	20.0	1.9	+10.5%
Net profit attributable to the Group	17.3	19.0	1.7	+9.9%

The consolidated interim financial statements were subject to a limited review by the statutory auditors.

Denis Supplisson, Chief Executive Officer of Equasens, commented: “The Group’s strong commercial and financial performance in the first half of 2026 highlights its ability to successfully implement its strategy, while maintaining disciplined management of costs and financial resources. Our recent acquisitions, particularly that of Erevo, are already contributing positively to our results, while the Pharmagest and Axigate Link divisions confirm the strength of our organic growth momentum. Despite a wait-and-see attitude in several of our markets and changes to some of our longstanding offerings, we continue to strengthen our position as the leader in digital healthcare solutions in Europe. This momentum is driven by clearly identified growth drivers: the integration of AI into our business software, developing our sovereign healthcare cloud offering and inclusion of our solutions under Wave 2 of France’s Ségur digital healthcare programme.”

Frédérique Schmidt, Chief Financial Officer of Equasens, added: “The Group’s profitability improved in H1 2026 in a challenging environment, confirming the strength of Equasens’ positioning and its recurring revenue business model, with ARR of €111.1 million. At the same time, our strong cash generation enables us to continue investing while retaining the flexibility to meet our procurement needs.”

H1 2026 revenue: 7.3% growth and excellent visibility

Revenue (€m)	H1 2025 Reported basis	H1 2026 Reported basis	Change / Reported basis		of which external growth	Of which Ségur Wave 2	Change / Like-for-like basis
H1 revenue	116.0	124.5	+8.5	+7.3%	6.3	0.6	+1.7	+1.4%

In H1 2026, Equasens recorded revenue of €124.5m, up 7.3%. This growth was primarily driven by acquisitions (Erevo and Novaprove/DIS), which contributed €6.3m, as well as the initial impact of Wave 2 of France’s Ségur digital healthcare investment programme (€0.6m). Like-for-like, revenue increased by 1.4%.

Revenue visibility remains excellent, with annual recurring revenue (ARR) of €111.1m at 30 June 2026, up 8.8% with a strong organic component. This momentum also extended to maintenance and subscription revenue, which increased by 8.4% (+4.7% like-for-like).

Trends differed by revenue type, with systems and equipment sales remaining stable at €47.0m (-0.3%), while software and services revenue increased by 24.9%, driven by acquisitions.

H1 2026 profitability: performance driven by multiple factors

Simplified H1 income statement (€m)	H1 2025 Reported basis	H1 2026 Reported basis	Change / Reported basis
Revenue	116.0	124.5	+8.5	+7.3%
Current EBITDA	29.8	33.3	+3.5	+11.9%
Current operating income	21.1	23.7	+2.5	+11.9%
Other operating expenses	-0.1	-0.2
Net financial income/(expense)	1.7	1.3
Income tax expense	-4.6	-4.8
Share of profits and losses of equity-accounted investments	–	0.1
Net profit	18.1	20.0	+1.9	+10.5%
Net profit attributable to the Group	17.3	19.0	+1.7	+9.9%
Basic earnings per share (in €)	1.15	1.26	+0.11	+9.9%

Current EBITDA amounted to €33.3m (+11.9%), representing a margin of 26.8%, with growth significantly outpacing that of revenue.

Current Operating Income increased by the same proportion, up 11.9% to €23.7m. The current operating margin thus reached 19.0%, an increase of 0.8 percentage points compared with H1 2025. The improvement in profitability was driven by several factors: a favourable product mix in terms of margins, tight control over expenses, particularly personnel expenses (+1.4% like-for-like), and the accretive contribution from acquisitions, representing 0.3 percentage points.

Net financial income decreased to €1.3m, notably reflecting a €0.3m increase in the cost of debt. Income tax expense amounted to €4.8m, representing an average tax rate of approximately 20%, including the impact of the IP Box regime¹.

Overall, net income increased by 10.5% to €20.0m, in line with the increase in operating income. Net profit attributable to owners of the parent amounted to €19.0m (+9.9%), representing basic earnings per share of €1.26 (€1.15 in H1 2025).

Analysis by Division: strong commercial and operating performances by Pharmagest and Axigate Link, with mixed trends across the other Divisions

H1 2026 revenue / Division (€m)	H1 2025 Reported basis	H1 2026 Reported basis	Change / Reported basis		of which external growth	Of which Ségur Wave 2	Change / Like-for-like basis
PHARMAGEST	85.9	89.0	+3.1	+3.6%	–	–	+3.1	+3.6%
AXIGATE LINK	16.5	19.8	+3.4	+20.4%	2.4	0.6	+0.4	+2.7%
E-CONNECT	7.5	6.2	-1.3	-17.4%	–	–	-1.3	-17.4%
MEDICAL SOLUTIONS	5.1	8.6	+3.5	+68.7%	3.9	–	-0.5	-8.9%
FINTECH	1.0	0.9	-0.1	-13.5%	–	–	-0.1	-13.5%
Total	116.0	124.5	+8.5	+7.3%	6.3	0.6	+1.7	+1.4%

H1 COI / DIVISION (€m)	H1 2025 Reported basis	H1 2026 Reported basis	Change / Reported basis		H1 2025 current operating margin	H1 2026 current operating margin
PHARMAGEST	14.1	16.6	+2.5	+17.9%	16.4%	18.6%
AXIGATE LINK	4.4	5.0	+0.7	+15.4%	26.6%	25.5%
E-CONNECT	2.7	2.4	-0.3	-12.5%	36.0%	38.2%
MEDICAL SOLUTIONS	0.3	-0.2	-0.5	-156.7%	6.7%	-2.3%
FINTECH	-0.3	-0.1	+0.2	+57.6%	-34.2%	-16.7%
Total	21.1	23.7	+2.5	+11.9%	18.2%	19.0%

PHARMAGEST Division:

• Revenue: €89.0m, +3.6%
• Current operating income: €16.6m, +17.9%
• Current operating margin: 18.6% (16.4% in H1 2025)

The Division’s innovation and European expansion strategy continued to support growth, with revenue up 4.3% in both France and Italy, particularly in the Pharmacy business. By revenue type, systems and equipment sales increased by 2.5% and maintenance and subscriptions by 6.1%, while software and services declined by 0.6%, reflecting the contraction of the training sector.
The Division delivered an excellent operating performance, driven by a favourable product mix, stable personnel expenses and a marked improvement in profitability in Italy (+€0.7m).

AXIGATE LINK Division:

• Revenue: €19.8m, +20.4%
• Current operating income: €5.0m, +15.4%
• Current operating margin: 25.5% (26.6% in H1 2025)

All of the Division’s business lines recorded growth: Nursing Homes (+0.3%), Home Care (+15.1%) and Hospitals (+18.5% like-for-like). With revenue of €4.8m in H1, Hospitals became the Division’s second-largest contributor. Excluding acquisitions (€2.4m) and the impact of Wave 2 of the Ségur programme (€0.6m), growth was 2.7%.

The Division has maintained an excellent level of performance compared with its peers, while continuing to invest significantly and benefiting from Wave 2 of the Ségur programme and the momentum of its Hospitals and Hospital-at-Home business lines.

E-CONNECT Division:

• Revenue: €6.2m, -17.4%
• Current operating income: €2.4m, -12.5%
• Current operating margin: 38.2% (36.0% in H1 2025)

The Division’s business was affected by a wait-and-see approach among healthcare professionals amid economic uncertainty, as well as the slow rollout of the Carte Vitale health insurance card app.

Stable revenue and margins in the Pharmacy business, combined with lower expenses across the Division, helped offset the decline in mobility solutions and improve the operating margin.

In the fixed solutions segment, the product range was expanded in June 2026 with the launch of the new KAP-4CV reader. This compact, elegantly designed solution enables healthcare professionals to access all data media, regardless of whether the French national insurance Carte Vitale card is presented in physical form or digitally on a smartphone. This new reader will fully support the rollout of the Carte Vitale insurance card app.

The market remains sensitive to the economic environment, while ongoing supply chain disruptions are expected to put pressure on production costs. To secure its production capacity over the medium term, the Division has increased advance orders from suppliers of critical components. Nevertheless, it remains exposed to ongoing pressures affecting the availability and cost of certain components.

MEDICAL SOLUTIONS Division:

• Revenue: €8.6m, +68.7%
• Current operating income: -€0.2m (€0.3m at H1 2025)
• Current operating margin: -2.3% (6.7% in H1 2025)

The Division’s growth was driven by acquisitions (€3.9m). Like-for-like, revenue declined by 8.9%. The commercialisation of new features and the new structure of the sales network are expected to support a return to organic growth.

Current operating income reflects the investments made as part of the transformation of legacy offerings, which are requiring significant development and marketing efforts (EQWO, the app that simplifies the patient–practitioner relationship, notably with the rollout of the online scheduling module; LOQUii, the sovereign AI dedicated to real-time transcription of caregiver–patient interactions; Wave 2 of the Ségur digital health initiative). These investments are partially offset by the meaningful contribution from external growth (€0.5m).

FINTECH Division:

• Revenue: €0.9m, -13.5%
• Current operating income: -€0.1m (-€0.3m at H1 2025)
• Current operating margin: -16.7% (-34.2% in H1 2025)

With lessors remaining cautious and interest rates volatile, the Division stabilised its business and reduced its operating loss through tighter risk management.

Simplified balance sheet at 30 June 2026: increase in net cash and higher inventory levels to secure operating activities

Assets (€m)	31/12/2025	30/06/2026	Liabilities (€m)	31/12/2025	30/06/2026
NON-CURRENT ASSETS	271.8	292.0	SHAREHOLDERS’ EQUITY	263.0	260.9
Research and development	39.3	39.4	Attributable to the Group	252.3	250.0
Goodwill	128.0	128.0	NON-CURRENT LIABILITIES	59.6	54.7
Non-current financial assets	50.4	71.2	Non-current provisions	9.0	9.2
Other non-current assets	54.1	53.3	Long-term financial liabilities	33.6	28.2
			Other non-current liabilities	16.9	17.4
CURRENT ASSETS	167.2	158.8	CURRENT LIABILITIES	116.4	135.2
Trade receivables	48.5	48.3	Short-term debt	20.2	18.9
Other current assets	31.6	41.5	Trade payables	19.7	22.8
Current financial assets	53.0	48.9	Other current liabilities	76.5	93.6
Cash and cash equivalents	34.1	20.1
Total	439.0	450.8	Total	439.0	450.8

Cash position (€m)	31/12/2025	30/06/2026
Gross cash	136.8	140.2
Net cash	83.6	93.2

Non-current assets changed little over the period, with the exception of non-current financial assets (€71.2m compared with €50.4m at 31 December 2025), reflecting the investment of a portion of available cash in EMTNs.

Other current assets increased significantly to €41.5m, compared with €31.6m at 31 December 2025, notably reflecting an €8.5m increase in equipment inventories to secure supplies and prices.

Net cash increased to €93.2m (€83.6m at 31 December 2025), reflecting the Group’s continued low level of debt.

Simplified H1 2026 cash flow statement: strong cash flow generation supporting increased operating investment and higher equipment inventories to secure supplies

H1 Cash flow:	H1 2025	H1 2026
Operating cash flows	29.6	33.1
Interest and tax	-4.8	-6.6
Cash flow after interest and tax	24.8	26.5
Change in working capital	0.5	-11.5
Capital expenditures	-6.1	-6.7
Financial investments and income from cash flow	1.0	1.8
Dividends paid	–	–
Borrowings and financial liabilities (1)	-12.3	-9.5
Change in cash and cash equivalents (before acquisitions and disposals of financial investments)	7.9	0.6
Acquisitions and disposals of financial investments	-5.1	-14.7
Change in gross cash position	2.8	-14.1

⁽¹⁾ Including IFRS16

Cash flow from operations reached €33.1m, up €3.5m, in line with the increase in EBITDA. After interest and taxes, it amounted to €26.5m.

Part of these cash flows was temporarily deployed to fund working capital requirements, resulting in a €11.5m cash outflow linked to the build-up of equipment inventories.

Operating investments amounted to €6.7m, of which €5.3m was primarily allocated to development activities.

Finally, loan repayments amounted to €12.6m, including €2.1m relating to IFRS 16, while a new €3.5m loan was taken out to finance the remaining portion of the 2025 acquisitions.

Outlook

The Group intends to strengthen its position as a leading provider of digital solutions for healthcare professionals and facilities in France and Europe, drawing on a portfolio that covers the entire care continuum, strong market penetration, and a business model based on recurring revenue and high customer retention.

Technological innovation remains at the core of the Group’s strategy, with interoperability, stakeholder coordination and improved efficiency of healthcare activities as key priorities. In this context, artificial intelligence is a major focus for developing and enhancing the Group’s offering. Equasens is continuing to embed AI into its vertical software solutions and to develop new SaaS-based functionalities, hosted on its private healthcare cloud. More specifically, the Group aims to master the agentic AI layer, which will automate certain tasks, analyse large volumes of data in real time and support healthcare professionals in their decision-making, with the objective of delivering ever greater day-to-day value to healthcare professionals.

The Group also intends to take full advantage of Wave 2 of the Ségur Reform, the initial effects of which were recorded in the first half of the year and whose deployment schedule extends through the first half of 2027.
The decisions made regarding growth drivers confirm the relevance of the strategic directions: development of new services, SaaS and cloud solutions, integration of AI, and expansion into new target markets. This momentum is further supported by the complementary nature of the Group’s business lines and solutions.

Finally, Equasens’ financial strength—based on profitability, recurring revenue, and business diversification—enables it to pursue targeted investments in high-potential segments and to align its development with a long-term perspective, thereby supporting the digital transformation of the healthcare sector.

Financial calendar:

• Publication of Q3 2026 revenue: 29 October 2026 (after market close)

About Equasens Group

Founded over 40 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1,500 people across Europe.
Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.
And reflecting the spirit of its tagline “Technology for a More Human Experience”, the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.
 Listed on Euronext Paris™ – Compartment B

Indexes: MSCI GLOBAL MICRO CAP – GAÏA Index 2020 – CAC^® SMALL and CAC^® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” – SRD) and equity savings accounts invested in small and mid caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS 

Get all the news about Equasens Group www.equasens.com and on LinkedIn

Investor Relations and Media Contacts

Equasens Group Investor Relations  Chief Financial Officer Frédérique Schmidt Tel.: + 33 (0)3 83 15 90 67 frederique.schmidt@equasens.com

NewCap Investor Relations Thomas Grojean Louis-Victor Delouvrier Tel: + 33 (0)1 44 71 94 94 equasens@newcap.eu

NewCap Financial media relations Nicolas Mérigeau Tel: + 33 (0)1 44 71 94 94 equasens@newcap.eu

Forward-looking statements
This press release contains forward-looking statements that are not guarantees of future performance and are based on current opinions, forecasts and assumptions, including, but not limited to, assumptions about Equasens’ current and future strategy and the environment in which Equasens operates. These involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to materially differ from those expressed in or implied by such forward-looking statements. These risks and uncertainties include those detailed in Chapter 3 “Risk factors” of the Universal Registration Document filed with the French financial market authority (Autorité des Marchés Financiers or AMF) on April 29, 2026 under number D.26-0320. These forward-looking statements are valid only as of the date of this press release.

---

1 The IP BOX regime is designed to support innovation and retain intellectual property assets, including original software, in France by reducing the tax burden on companies investing in R&D in the country. These companies benefit from a reduced corporate income tax rate of 10% on eligible net income from their copyright-protected software assets.

Attachment

• CP_EQUASENS_Résultats semestriels 2026_EN

28 SEPTEMBER 2026

NORTHERN 3 VCT PLC

TRANSACTION IN OWN SHARES 

Northern 3 VCT PLC (“the Company”) announces that on 25 September 2026 it purchased for cancellation under an existing authority granted by shareholders 1,145,021 ordinary shares of 5p each in the market at a price of 81.70p per share, representing approximately 0.65% of the Company’s issued ordinary share capital. There remain 175,856,561 ordinary shares in issue. 

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), the Company notifies the market that the capital of the Company consists of 175,856,561 ordinary shares with a nominal value of 5p each. All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 175,856,561 (“the Figure”). The Figure may be used by a shareholder or other person as the denominator for the calculations by which they will determine if they are required to notify the voting rights they hold in relation to the Company, or a change to those voting rights, under the DTRs. 

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Siris to acquire Active Ownership’s 19.1% stake in Agfa-Gevaert NV

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV today announced that Siris Capital Group (together with its affiliates, “Siris”) has signed a strategic investment in Agfa-Gevaert NV, to acquire a 19.1% stake currently held by Active Ownership. Terms of the transaction were not disclosed.

The transaction is subject to the closing of the previously announced agreement to combine Agfa’s Digital Printing Solutions business (“Agfa DPS”) with Electronics for Imaging, Inc. (“EFI”), a Siris portfolio company, which in turn is subject to customary regulatory approvals and closing conditions.

Frank Baker, Co-Founder and Managing Partner of Siris, said: “Agfa is a company with nearly 160 years of history, differentiated technical expertise and leading positions across attractive end markets. Through our work with the Agfa team on the EFI-Agfa DPS combination, we have gained an even deeper appreciation for the strength of the business, the quality of its people and the significant opportunities ahead. We are excited to deepen our partnership with Agfa and to serve as a constructive shareholder as the company continues to invest in its growth businesses and build on the transformation underway across the company.”

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

About Siris
Siris is a leading private equity firm focused on control investments in services businesses that enable transformative technologies to scale. The firm invests in companies that support the underlying infrastructure for these technologies and help enterprises integrate them into critical operational workflows. Based in West Palm Beach, Florida, Siris has deployed more than $9 billion of equity capital since inception. www.siris.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

• press release in pdf